SP140L: A Potential Drug Target and Biomarker (G93349)

Target Name: SP140L

NCBI ID: G93349

SP140L

SP140L: A Potential Drug Target and Biomarker

SP140L, short for short for SPhingomyelinyl Phosphate (SMIP), is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the intracellular signaling pathway known as the baggage pathway, which is involved in the regulation of cellular processes such as cell adhesion, migration, and survival. SP140L has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, SP140L has emerged as a promising drug target and biomarker.

SP140L is a member of the family of phospholipase C (PLC) enzymes, which are involved in the breakdown of phospholipids. PLC enzymes are critical for the regulation of cellular signaling pathways, including the baggage pathway. This pathway is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival. SP140L is specifically involved in the regulation of the baggage pathway, which is known for its role in the regulation of cell-cell adhesion.

SP140L has been shown to play a critical role in the regulation of cell-cell adhesion. During the cell-cell adhesion process, SP140L helps to ensure that cells stick together and form tissues. This is important for the development and maintenance of tissues and organs , as well as for the proper functioning of the immune system.

SP140L has also been shown to play a role in the regulation of cancer progression. Many studies have shown that SP140L is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, research has suggested that SP140L may be involved in the development and progression of certain types of cancer, such as melanoma and lung cancer. As a result, SP140L has emerged as a potential drug target for cancer treatment.

SP140L has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and progression of other diseases, including cardiovascular disease and neurodegenerative diseases. For example, research has shown that SP140L is involved in the regulation of the production of reactive oxygen species (ROS), which can cause damage to cells and contribute to the development of certain cardiovascular diseases. Additionally, SP140L has been shown to play a role in the regulation of the production of pro-inflammatory cytokines, which can contribute to the development and progression of neurodegenerative diseases.

SP140L has also been shown to be involved in the regulation of cellular signaling pathways that are involved in the regulation of pain perception and neurotransmission. This is important for the development of pain-resistant therapies, as well as for the study of neurodegenerative diseases.

In conclusion, SP140L is a protein that is involved in the regulation of various cellular signaling pathways that are involved in the development and progression of diseases. As a result, SP140L has emerged as a promising drug target and biomarker. Further research is needed to fully understand the role of SP140L in the regulation of cellular processes and the development and progression of diseases.

Protein Name: SP140 Nuclear Body Protein Like

The "SP140L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SP140L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets